You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

49 Results
Guidelines and Advice
Status: Archived
ID: CED 10
Sep 2008
Guidelines and Advice
Status: Archived
ID: CED 9
Aug 2008
Guidelines and Advice
Status: Archived
ID: CED 8
Jul 2008
Guidelines and Advice
Status: Archived
ID: CED 7
Feb 2008
Guidelines and Advice
Status: Archived
ID: 1-13
Sep 2008
Guidelines and Advice
Status: Archived
ID: 3-19
Feb 2008
Guidelines and Advice
Status: Education and Information
ID: 19-2
Mar 2008
Guidelines and Advice
Status: Archived
ID: 16-2
Mar 2008
Guidelines and Advice
Status: Archived
ID: 6-14
Dec 2008
Guidelines and Advice
Status: Archived
ID: 6-9
Jan 2008
Statistical Reports
Dec 2008
Regimen
Cancer Type:
Genitourinary, 
Prostate
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    niraparib / abiraterone - For the treatment of metastatic castration resistant prostate cancer in patients with a BRCA mutation
ODB - General Benefit
    prednisone
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
niraparib / abiraterone,
prednisone
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jun 2025

Pages